Transcatheter aortic valve replacement in obese patients: procedural vascular complications with the trans-femoral and trans-carotid access routes.


Journal

Interactive cardiovascular and thoracic surgery
ISSN: 1569-9285
Titre abrégé: Interact Cardiovasc Thorac Surg
Pays: England
ID NLM: 101158399

Informations de publication

Date de publication:
01 06 2022
Historique:
received: 27 07 2021
revised: 12 10 2021
accepted: 20 11 2021
pubmed: 24 12 2021
medline: 7 6 2022
entrez: 23 12 2021
Statut: ppublish

Résumé

Obesity may increase the risk of vascular complications in transfemoral (TF) transcatheter aortic valve replacement (TAVR) procedures. The transcarotid (TC) approach has recently emerged as an alternative access in TAVR. We sought to compare vascular complications and early clinical outcomes in obese patients undergoing TAVR either by TF or TC vascular access. Multicentre registry including obese patients undergoing TF- or TC-TAVR in 15 tertiary centres. All patients received newer-generation transcatheter heart valves. For patients exhibiting unfavourable ileo-femoral anatomic characteristics, the TC approach was favoured in 3 centres with experience with it. A propensity score analysis was performed for overcoming unbalanced baseline covariates. The primary end point was the occurrence of in-hospital vascular complications (Valve Academic Research Consortium-2 criteria). A total of 539 patients were included, 454 (84.2%) and 85 (15.8%) had a TF and TC access, respectively. In the propensity-adjusted cohort (TF: 442 patients; TC: 85 patients), both baseline and procedural valve-related characteristics were well-balanced between groups. A significant decrease in vascular complications was observed in the TC group (3.5% vs 12% in the TF group, odds ratio: 0.26, 95% CI: 0.07-0.95, P = 0.037). There were no statistically significant differences between groups regarding in-hospital mortality (TC: 2.8%, TF: 1.5%), stroke (TC: 1.2%, TF: 0.4%) and life-threatening/major bleeding events (TC: 2.8%, TF: 3.8%). In patients with obesity undergoing TAVR with newer-generation devices, the TC access was associated with a lower rate of vascular complications. Larger randomized studies are warranted to further assess the better approach for TAVR in obese patients.

Identifiants

pubmed: 34942005
pii: 6481776
doi: 10.1093/icvts/ivab354
pmc: PMC9159419
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

982-989

Subventions

Organisme : Fundación Alfonso Martín Escudero

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.

Références

CMAJ. 2020 Aug 4;192(31):E875-E891
pubmed: 32753461
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
J Am Coll Cardiol. 2012 Oct 9;60(15):1438-54
pubmed: 23036636
Am J Cardiol. 2018 Apr 01;121(7):856-861
pubmed: 29415808
Neth Heart J. 2017 Sep;25(9):498-509
pubmed: 28536936
Am J Cardiol. 2004 Nov 1;94(9):1174-7
pubmed: 15518615
JACC Cardiovasc Interv. 2019 Apr 8;12(7):662-669
pubmed: 30947940
J Am Coll Cardiol. 2017 Jul 4;70(1):42-55
pubmed: 28662806
J Am Heart Assoc. 2020 Oct 20;9(19):e017460
pubmed: 32990146
Circ Cardiovasc Interv. 2018 Nov;11(11):e006388
pubmed: 30571205
Circ J. 2018 Sep 25;82(10):2518-2522
pubmed: 30068794
J Am Heart Assoc. 2020 Nov 3;9(21):e018042
pubmed: 33103545
Am J Cardiol. 2009 Feb 15;103(4):507-11
pubmed: 19195511
Catheter Cardiovasc Interv. 2016 Jul;88(1):118-24
pubmed: 26715505
Ann Thorac Surg. 2020 Jan;109(1):49-56
pubmed: 31279787
Can J Cardiol. 2016 Dec;32(12):1575.e9-1575.e12
pubmed: 27181189
J Thorac Cardiovasc Surg. 2022 Jan;163(1):69-77
pubmed: 32387164
Am J Cardiol. 2013 Jan 15;111(2):231-6
pubmed: 23102879
Mayo Clin Proc. 2020 Jan;95(1):57-68
pubmed: 31902429
N Engl J Med. 2017 Apr 6;376(14):1321-1331
pubmed: 28304219
Am J Cardiol. 2017 Nov 15;120(10):1858-1862
pubmed: 28860018
Int J Cardiol. 2017 Sep 15;243:126-131
pubmed: 28595747
N Engl J Med. 2011 Jun 9;364(23):2187-98
pubmed: 21639811
Pharmacoeconomics. 2015 Jul;33(7):673-89
pubmed: 25471927

Auteurs

Alberto Alperi (A)

Quebec Heart & Lung Institute, Laval University, Quebec City, Canada.

Angela McInerney (A)

Cardiovascular Institute, Hospital Clinico San Carlos, Madrid, Spain.

Thomas Modine (T)

Centre Hospitalier Universitaire de Lille, Lille, France.

Chekrallah Chamandi (C)

Hôpital européen Georges-Pompidou, Paris, France.

Jose D Tafur-Soto (JD)

The Ochsner Clinical School, Ochsner Medical Center, New Orleans, LA, USA.

Marco Barbanti (M)

Ferrarotto Hospital, University of Catania, Catania, Italy.

Diego Lopez (D)

CIVERCV, Instituto de investigación de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.

Francisco Campelo-Parada (F)

Cardiology Department, Rangueil University Hospital, Toulouse, France.

Asim N Cheema (AN)

Division of Cardiology, St Michaels Hospital, Toronto, Canada.

Stefan Toggweiler (S)

Heart Center Luzerne, Luzerner Kantonsspital, Lucerne, Switzerland.

Francesco Saia (F)

Cardiology Unit, Cardio-Thoracic-Vascular Department, University Hospital of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.

Ignacio Amat-Santos (I)

CIBERCV, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

Juan F Oteo (JF)

Department of Cardiology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.

Viçent Serra (V)

Hospital General Universitari Vall d'Hebron, Barcelona, Spain.

Maciej Dabrowski (M)

Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland.

Ramzi Abi-Akar (R)

Hôpital européen Georges-Pompidou, Paris, France.

Natalia Giraldo Echavarria (NG)

The Ochsner Clinical School, Ochsner Medical Center, New Orleans, LA, USA.

Roberto Valvo (R)

Ferrarotto Hospital, University of Catania, Catania, Italy.

Javier Lopez-Pais (J)

CIVERCV, Instituto de investigación de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.

Anthony Matta (A)

Cardiology Department, Rangueil University Hospital, Toulouse, France.

Mobeena Arif (M)

Division of Cardiology, St Michaels Hospital, Toronto, Canada.

Federico Moccetti (F)

Heart Center Luzerne, Luzerner Kantonsspital, Lucerne, Switzerland.

Miriam Compagnone (M)

Cardiology Unit, Cardio-Thoracic-Vascular Department, University Hospital of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.

Siamak Mohammadi (S)

Quebec Heart & Lung Institute, Laval University, Quebec City, Canada.

Luis Nombela-Franco (L)

Cardiovascular Institute, Hospital Clinico San Carlos, Madrid, Spain.

Josep Rodés-Cabau (J)

Quebec Heart & Lung Institute, Laval University, Quebec City, Canada.
Hospital Clínic Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH